Eur J Cancer Clin Oncol. 1983 Jan;19(1):39-42. doi: 10.1016/0277-5379(83)90395-4.
The effect of misonidazole on the duration of the free interval (time to recurrence) and total survival of adults bearing malignant supratentorial brain gliomas was measured in a randomized double-blind study. Radiotherapy consisted of 9 X 3.5 Gy fractions given on alternate days during 3 weeks followed by 6 X 3-Gy fractions delivered in 2 weeks. Misonidazole, 1.3 g/m2, administrated 4 hr before the 9 first irradiations to 82 patients, had no effect on the duration of the free interval or total survival compared with 81 controls. The two groups were comparable in respect to the main prognostic factors: median age, performance status or tumour location. The overall tolerance of misonidazole was good.
在一项随机双盲研究中，测定了米索硝唑对患有幕上恶性脑胶质瘤的成年人的无瘤间期（复发时间）和总生存期的影响。放疗包括在3周内隔日给予9次3.5 Gy分割剂量，随后在2周内给予6次3 Gy分割剂量。82例患者在首次9次照射前4小时给予1.3 g/m²的米索硝唑，与81例对照组相比，米索硝唑对无瘤间期或总生存期没有影响。两组在主要预后因素方面具有可比性：中位年龄、功能状态或肿瘤位置。米索硝唑的总体耐受性良好。
